FDA approves durvalumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer
AZN•The FDA approved durvalumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer.
1. FDA approval
The FDA approved durvalumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer.
